Julian Schulze zur Wiesch

Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study

C. Bokemeyer, M. Sinn, G. Schön, 2022, Cancer Cell.

Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro

J. Wellbrock, L. Oliveira-Ferrer, T. Sturmheit, 2023, Frontiers in Immunology.

SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition

E. Willscher, L. Bosurgi, L. Paschold, 2024, NPJ vaccines.